[Bromocriptine treatment of hyperprolactinemia].
In 36 female patients with microprolactinoma was carried out a primary therapy and in 19 patients (10 males, 9 females) with a postoperatively persisting hyperprolactinaemia a secondary therapy with bromocriptine. In close correlation between the PRL-levels and the bromocriptine dose we achieved a normalisation of the hormone levels in the microprolactinomas. A normalisation of the cycle was observed in 80%, a persisting of the galactorrhoea in about 90% and a conception in nearly two thirds of the women. Also in those patients who underwent a secondary therapy in nearly 80% a decrease of the PRL-levels into the normal region developed. In a longterm therapy with bromocriptine a reduction of the dose may become possible, so that controls of the hormone levels are necessary in larger intervals. Most side effects of a bromocriptine treatment are transitory.
D000236:Adenoma / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*; D014057:Tomography, X-Ray Computed
D001971:Bromocriptine; D011388:Prolactin
Bromocriptin-Behandlung bei Hyperprolaktinämie.